Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangdong Biolight Meditech Co., Ltd. (300246.SZ)
Zhuhai, CN
Guangdong Biolight Meditech Co., Ltd., founded in 1993 and headquartered in Zhuhai, China, operates as a global enterprise. The company is dedicated to the full spectrum of medical technology, encompassing the research, development, commercialization, sales, and after-sales service of various medical devices, consumables, and integrated healthcare solutions. Its extensive product portfolio includes patient and fetal monitors, ECG machines, hemodialysis equipment, homecare medical products, and specialized items such as medical pumps and veterinary monitors, along with related accessories. Biolight Meditech maintains a broad international footprint, delivering its offerings to markets across Asia, Africa, Europe, North America, and Latin America.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.01% | -17.97% | -3.56% | +27.39% | +95.98% | +110.74% | +127.90% | +42.01% | +33.05% | -16.61% | +112.31% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+3.3% Q1'26: -1.9% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+3.7% Q1'26: -151.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-5.5% Q1'26: -12.3% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-4.4% Q1'26: -4.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-3.6% Q1'26: -2.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.8% Q1'26: -1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×29.45× Q1'26: -19.32× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
380.51M
est: 347.00M (+9.7%)
|
594.31M
est: 654.00M (-9.1%)
|
711.47M
est: 347.00M (+105.0%)
|
813.39M
est: 654.00M (+24.4%)
|
825.96M
est: 912.00M (-9.4%)
|
1.40B
est: 1.15B (+21.6%)
|
1.09B
est: 1.18B (-7.9%)
|
1.18B
est: 1.42B (-16.9%)
|
1.19B
est: 1.42B (-16.2%)
|
1.06B
est: 1.68B (-36.7%)
|
1.10B
est: 1.95B (-43.8%)
|
| EBITDA |
44.11M
est: 40.03M (+10.2%)
|
104.16M
est: 75.45M (+38.1%)
|
99.59M
est: 40.03M (+148.8%)
|
108.04M
est: 75.45M (+43.2%)
|
112.16M
est: 105.21M (+6.6%)
|
447.90M
est: 132.44M (+238.2%)
|
126.19M
est: 136.59M (-7.6%)
|
77.97M
est: 164.28M (-52.5%)
|
19.42M
est: 164.28M (-88.2%)
|
14.90M
est: 79.33M (-81.2%)
|
27.35M
est: 92.26M (-70.4%)
|
| EBIT |
33.19M
est: 24.58M (+35.0%)
|
92.08M
est: 46.34M (+98.7%)
|
86.92M
est: 24.58M (+253.5%)
|
93.94M
est: 46.34M (+102.7%)
|
98.28M
est: 64.61M (+52.1%)
|
430.21M
est: 81.34M (+428.9%)
|
90.09M
est: 83.89M (+7.4%)
|
33.65M
est: 100.89M (-66.6%)
|
-30.94M
est: 100.89M (-130.7%)
|
-43.22M
est: -35.5K (-121,660.8%)
|
-48.68M
est: -41.3K (-117,815.7%)
|
| Net Income |
23.92M
est: 61.26M (-61.0%)
|
67.14M
est: 78.77M (-14.8%)
|
57.55M
est: 61.26M (-6.1%)
|
64.19M
est: 78.77M (-18.5%)
|
64.71M
est: 99.77M (-35.1%)
|
346.15M
est: 124.28M (+178.5%)
|
63.79M
est: 22.75M (+180.3%)
|
22.13M
est: 99.77M (-77.8%)
|
-65.19M
est: 99.77M (-165.3%)
|
-71.44M
est: 137.59M (-151.9%)
|
-69.43M
est: 179.92M (-138.6%)
|
| SGA |
114.36M
est: 40.62M (+181.6%)
|
151.89M
est: 76.55M (+98.4%)
|
146.25M
est: 40.62M (+260.1%)
|
170.06M
est: 76.55M (+122.2%)
|
180.37M
est: 106.75M (+69.0%)
|
153.28M
est: 134.37M (+14.1%)
|
201.14M
est: 138.58M (+45.1%)
|
262.56M
est: 166.67M (+57.5%)
|
254.10M
est: 166.67M (+52.5%)
|
261.52M
est: 324.07M (-19.3%)
|
111.51M
est: 376.89M (-70.4%)
|
| EPS |
0.11
est: 0.23 (-52.9%)
|
0.31
est: 0.30 (+3.3%)
|
0.26
est: 0.23 (+11.4%)
|
0.29
est: 0.30 (-3.3%)
|
0.30
est: 0.38 (-21.1%)
|
1.58
est: 0.47 (+233.8%)
|
0.29
est: 0.09 (+234.6%)
|
0.08
est: 0.38 (-77.7%)
|
-0.25
est: 0.38 (-165.8%)
|
-0.27
est: 0.52 (-151.9%)
|
-0.26
est: 0.68 (-138.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jinyuan Yan | Chairman & President | — | male |
| Shuyin Hu | Accounting Supervisor | — | — |
| Wei Xu | Financial Director & Director | — | female |
| Yongxing Yang | Vice President & Secretary of the Board of Directors | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300246.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
